Shares of Arrowhead Research Corp. (NASDAQ:ARWR) traded down 7.5% during mid-day trading on Wednesday . The company traded as low as $7.39 and last traded at $7.47, with a volume of 1,429,300 shares. The stock had previously closed at $8.08.

A number of analysts have issued reports on the company. Jefferies Group reaffirmed a “hold” rating and issued a $4.75 target price on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. Chardan Capital assumed coverage on Arrowhead Research Corp. in a research note on Thursday, May 19th. They issued a “buy” rating and a $12.00 target price for the company. Piper Jaffray Cos. cut their target price on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. William Blair assumed coverage on Arrowhead Research Corp. in a research note on Friday, August 19th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald assumed coverage on Arrowhead Research Corp. in a research note on Wednesday, August 17th. They issued a “buy” rating and a $15.00 target price for the company. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $10.44.

The company’s 50-day moving average price is $6.02 and its 200 day moving average price is $5.37. The stock’s market capitalization is $418.57 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. The business earned $39.58 million during the quarter, compared to analysts’ expectations of $0.05 million. The company’s revenue for the quarter was down 68.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.27) EPS. On average, equities analysts anticipate that Arrowhead Research Corp. will post ($1.31) earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.